Company news

Acumen Pharmaceuticals, Inc. news in 2024

Acumen Pharmaceuticals, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Acumen Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Highlights

November 11, 2024

Acumen Pharmaceuticals Appoints Dr. Amy Schacterle as Chief Regulatory Officer & Head of Quality

November 5, 2024

Acumen Pharmaceuticals Extends Collaboration with Lonza to Add Drug Product Manufacturing of Sabirnetug for Early Alzheimer’s Disease

September 25, 2024

Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024

September 24, 2024

Acumen Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Highlights

August 12, 2024

Acumen Pharmaceuticals Announces First Subject Dosed in Phase 1 Study of Subcutaneous Sabirnetug (ACU193) for Early Alzheimer’s Disease

July 28, 2024

Acumen Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Highlights

May 13, 2024

Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

May 7, 2024

Acumen Pharmaceuticals to Report First Quarter Results on May 14, 2024

May 6, 2024

Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer’s Disease

April 3, 2024

Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2023 and Business Highlights

March 25, 2024

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

March 20, 2024

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

March 18, 2024

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

February 20, 2024

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

January 31, 2024

Calls in 2024

Decks in 2024